Navigating the Transition from MDD/IVDD to MDR/IVDR: A Complex and Costly Journey

For many companies with CE-marked products under the Medical Device Directive (MDD) or In Vitro Diagnostic Directive (IVDD), the transition to the new Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has become a challenging and costly process. What once was a straightforward regulatory pathway now feels like navigating a maze, with stricter Notified Body requirements that are often complex and difficult to interpret.

Companies face increasing demands, such as splitting previously unified MDD files into multiple MDR dossiers. This adds complexity, significant regulatory costs, delays in market access, and operational strain.

The Loss of CE Certification

One of the most frustrating aspects of the transition is that many products—safely sold in the EU for decades—are losing their CE certifications. These products haven’t changed, nor have their safety profiles. The issue lies with the new, more bureaucratic regulatory framework introduced by MDR/IVDR, which prioritizes updated documentation and testing requirements over the actual safety of the devices.

Increased Administrative Burden

The new MDR/IVDR regulations impose documentation and testing standards that aren’t always tied to product safety, leading to frustration among regulatory affairs (RA) professionals. They must now explain to their management teams why previously compliant products face regulatory uncertainty—not due to safety concerns, but because the administrative rules have become more stringent.

Bridging the Gap Between Compliance and Business

Regulatory teams are caught in the middle, trying to meet compliance standards while explaining the financial and operational impacts to leadership. CEOs and executives naturally ask, “Why are we spending so much more, and why are our safe products suddenly at risk?” Communicating these complexities to a non-technical audience can be difficult, especially when the changes concern compliance rather than patient safety.

How Are Companies Responding?

How are you managing increased costs, longer timelines, and more rigorous audits? What strategies are you employing to ensure compliance while keeping your products on the market?

Let’s Share Insights

Expert guidance is essential for companies navigating the transition from MDD/IVDD to MDR/IVDR. Arazy Group’s regulatory professionals can help streamline this process, minimizing costs and reducing delays. Contact us today to learn how we can support your compliance journey.